Overview

Open-Label Study Evaluating Synera® in the Treatment of Patients With Carpal Tunnel Syndrome

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of the study is to explore the potential usefulness of Synera for the treatment of pain associated with mild to moderate carpal tunnel syndrome.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
ZARS Pharma Inc.
Treatments:
Lidocaine
Tetracaine
Criteria
Inclusion Criteria:

- Pain associated with mild to moderate carpal tunnel syndrome in a single wrist

- Have recent (within 3 months) electrodiagnostic evidence of carpal tunnel syndrome
(CTS)

Exclusion Criteria:

- Have bilateral carpal tunnel syndrome

- Have another peripheral neuropathy in the affected limb

- Have had an injection into the carpal tunnel within 8 weeks

- Have had surgical release of the target wrist within previous 6 months

- Have electrodiagnostic evidence of severe CTS

Other protocol-defined inclusion/exclusion criteria may apply